Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Chemotherapy for advanced gastric cancer.

Tytuł :
Chemotherapy for advanced gastric cancer.
Index Terms :
Anthracyclines/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Camptothecin/administration & dosage; Camptothecin/analogs & derivatives; Cisplatin/administration & dosage; Fluorouracil/administration & dosage; Humans; Randomized Controlled Trials as Topic; Stomach Neoplasms/drug therapy; Stomach Neoplasms/mortality; Taxoids/administration & dosage
Wydawca :
2017-08-29 info:eu-repo/date/embargoEnd/2018-08-29
Dodane szczegóły :
Wagner, A.D.
Syn, N.L.
Moehler, M.
Grothe, W.
Yong, W.P.
Tai, B.C.
Ho, J.
Unverzagt, S.
Typ dokumentu :
Zasób elektroniczny
Dostępność :
Open access content. Open access content
Restricted: cannot be viewed until 2018-08-29
Copying allowed only for non-profit organizations
Pozostałe numery :
Źródło wspomagające :
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
Zasób elektroniczny
Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies are currently limited to HER-2 positive disease treated with trastuzumab, in combination with chemotherapy, in first-line. In second-line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen. To assess the efficacy of chemotherapy versus best supportive care (BSC), combination versus single-agent chemotherapy and different chemotherapy combinations in advanced gastric cancer. We searched the Cochrane Central Register of Controlled Trials, MEDLINE and Embase up to June 2016, reference lists of studies, and contacted pharmaceutical companies and experts to identify randomised controlled trials (RCTs). We considered only RCTs on systemic, intravenous or oral chemotherapy versus BSC, combination versus single-agent chemotherapy and different chemotherapy regimens in advanced gastric cancer. Two review authors independently identified studies and extracted data. A third investigator was consulted in case of disagreements. We contacted study authors to obtain missing information. We included 64 RCTs, of which 60 RCTs (11,698 participants) provided data for the meta-analysis of overall survival. We found chemotherapy extends overall survival (OS) by approximately 6.7 months more than BSC (hazard ratio (HR) 0.3, 95% confidence intervals (CI) 0.24 to 0.55, 184 participants, three studies, moderate-quality evidence). Combination chemotherapy extends OS slightly (by an additional month) versus single-agent chemotherapy (HR 0.84, 95% CI 0.79 to 0.89, 4447 participants, 23 studies, moderate-quality evidence), which is part

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies